Pharmaceutical Executive-12-01-2022

Emerging biopharma companies are critical to the vibrancy of the healthcare landscape, but their long road of drug development fails to translate to successful market launch more often than it does for large pharma. What can be done to improve those odds?

Our annual report spotlighting notable investments in new drug development captures a mix of gradual gains and giant leaps—both equally as promising—in five expanding and diverse therapeutic areas: spinal muscular atrophy, hemophilia A, intranasal and inhaled vaccines, gene-targeted therapy, and RNA therapeutics.

Kimberly Moran, head of rare diseases in the US for UCB, started off working in medicine but quickly learned the importance of the business side of industry—and its role in helping improve the diagnosis and access paths for underserved patient segments.

Will biopharma investment heat up and signal better fortunes for 2023?

Whether pharma or FDA, healthcare outreach more visible than ever.

Companies should search within to gain talent edge.

No shortage of views being expressed on drug shortages.

Year characterized by mix of key advances, contentious stances.

Experts in attendance at Pharma 2022 share insights on medical affairs.

Click the title above for a link to open the Pharmaceutical Executive December 2022 issue in an interactive PDF format.

Virtual audits proving to be beneficial post-COVID despite continuing challenges.